With a 70-year legacy in #CardiovascularDisease (CVD) research, our philosophy has always been to help improve the lives of patients living with cardiovascular conditions. At #ACC25, we’re presenting new real-world and clinical data on our research in symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Explore how we’re working to advance care for those living with CVD: https://bit.ly/43zIdY5
In the U.S. studies have shown that symptomatic oHCM leads to hospitalization rates eight times higher than controls and incremental costs exceeding $35,000 per year compared to asymptomatic patients. Will be interesting to review real-world & clinical data to assess the long-term safety, effectiveness, and durability of therapies, which is often beyond the scope of randomized clinical trials.